BRIEF-Coherus Biosciences announces positive topline 24-week treatment Phase 3 results for CHS-1420 in patients with Psoriasis

* Coherus Biosciences announces positive topline 24-week

treatment phase three results for CHS-1420 (HUMIRA biosimilar

candidate) in patients with Psoriasis

Read more